ZyVersa Therapeutics
@ZyVersaThera
Followers
2K
Following
2
Media
250
Statuses
317
ZyVersa (Nasdaq: $ZVSA) is committed to developing biopharmaceuticals that address unmet medical needs of patients with inflammatory and renal diseases.
Joined December 2022
ZyVersa’s CEO is hopeful that Emergency Compassionate Use of VAR 200 in the patient with ApoCII amyloidosis will help improve the course of the disease and improve the patient’s quality of life. Learn why.
1
0
0
Evidence of lipotoxic glomerular injury in the patient ApoCII Amyloidosis prompted Dr. Fornoni to request Emergency Compassionate Use of VAR 200. Learn more.
0
0
0
Cholesterol Efflux Mediator™ VAR 200 was authorized by FDA for Emergency Compassionate Use in a patient with ApoCII Amyloidosis. Learn why.
3
0
0
Despite newer kidney drug treatments, over 130,000 US patients annually progress to renal failure, and >800,000 patients currently require dialysis or transplant to sustain life. Learn how VAR 200 will fit in the treatment algorithm.
0
0
0
VAR 200 has preclinical data in 3 different kidney diseases showing that alleviating lipotoxicity improves outcomes. Learn more:
1
0
0
VAR 200 is a potential first-in-class treatment for kidney disease addressing renal lipotoxicity. Learn why this is important.
0
0
0
Study authors concluded that their findings conclusively demonstrate that microglia-driven inflammation alone can trigger the full range of pathological features observed in neurodegenerative diseases. Learn why.
0
0
0
ZyVersa’s CEO indicated that this study supports our recently published data showing that IC 100 reduced microglial inflammation by inhibiting NLRP1 inflammasome activation, and that it improved clearance of toxic phosphorylated alpha synuclein. Learn more.
0
1
1
Study shows microglial-driven inflammation leads to propagation of phosphorylated α-synuclein and tau proteins that lead to neurodegeneration in Parkinson’s and Alzheimer’s diseases respectively. Learn more.
0
0
0
Learn about Inflammasome ASC Inhibitor IC 100’s preclinical data supporting its role in attenuation of obesity comorbidities.
0
0
0
Learn how Inflammasome ASC Inhibitor IC 100’s unique mechanism of action is expected to improve attenuation of obesity comorbidities.
0
0
0
GLP-1 agonists have revolutionized obesity treatment, but unmet needs exist. Learn how inflammasome inhibitors can meet those needs.
0
0
0
Leading inflammasome expert, Dr. Robert W. Keane, said therapeutics against inflammasomes and ASC specks are promising targets in Parkinson’s, Alzheimer’s, and lewy body Diseases. Learn why.
0
0
0
ZyVersa’s CEO indicated that the newly published data strengthen support for IC 100 as a potential disease-modifying drug for Parkinson’s disease. Learn more.
0
0
0
ZyVersa’s Inflammasome ASC Inhibitor IC 100 is expected to achieve value-building milestones this year. Learn more.
0
0
0
RT @LongevityTech: Study finds inflammation-targeting drug has Parkinson’s potential. #longevity #biotech #Parkinsons #inflammatio. https:/….
0
4
0
Newly published data suggest that ZyVersa’s Inflammasome ASC Inhibitor IC 100 has potential to slow progression of Parkinson’s disease. Learn more.
0
0
0
Several inflammasome inhibitors are in Phase 1b & Phase 2 trials. Learn which indications are being evaluated.
0
0
0
Several inflammasome inhibitors have demonstrated safety & promising signals of efficacy in preclinical/P1 programs. Learn more.
0
0
0
kidney failure. Learn the status of its development:
0
0
0